This application of the Toledo Community Clinical Oncology Program (TCCOP) seeks funding for continuation of its ongoing clinical trials and cancer control research. TCCOP has an impressive track record of increasing accrual to clinical trials and cancer control research extending over a 15 year period. TCCOP has been very successful in accruing to the protocols provided by the North Central Cancer Treatment Group (NCCTG) as its primary research base. In addition, participation in the Breast Cancer Prevention Trial with 87 subjects has been a challenge and learning experience. With this first chemoprevention trial underway, the Prostate Cancer Prevention Trial (PCPT) was easily implemented in a similar manner. The PCPT exceeded anticipated first year accrual with 112 randomized and another 28 still in the enrollment phase. The effort to continue or surpass previous accrual level will focus attention on methods to increase investigator awareness of high priority protocols. Cancer control activity will concentrate on the Prostate Cancer Prevention Trial and chemoprevention of secondary lung cancer and colon cancer. TCCOP will continue to enable physicians and allied health professionals to contribute to scientific activities through attendance at Group meetings, service on Committees, as well as increasing the number of chairmanships of protocol studies. TCCOP is sensitive to the scientific integrity of clinical research and will initiate procedures which address codes of conduct for research personnel. Quality control for research studies continues to be a strength of the Toledo CCOP. Finally, TCCOP foresees a continuous commitment of resources and support from the consortium of institutions and physicians.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035415-15
Application #
2712580
Study Section
Special Emphasis Panel (SRC (16))
Program Officer
Dunn, Barbara K
Project Start
1983-09-15
Project End
2000-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Toledo Community Hospital Oncology Prog
Department
Type
DUNS #
City
Toledo
State
OH
Country
United States
Zip Code
43617
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Tan, A D; Novotny, P J; Kaur, J S et al. (2016) QOL and Survival Comparisons by Race in Oncology Clinical Trials. J Cancer Clin Oncol 2:
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43
Dueck, A C; Singh, J; Atherton, P et al. (2015) Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 26:1971-7
Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26

Showing the most recent 10 out of 130 publications